Targeting CD20+ Rituxan resistant B-cells with anti-CD3 activated T cells (ATC) armed with anti-CD3 x anti-CD20 (CD20Bi)

被引：0
|
作者：
Gall, JM
Grabert, RC
Deavers, M
Davoll, PA
Lum, LG
机构：
[1] Roger Williams Med Ctr, Providence, RI USA
[2] Boston Univ, Boston, MA 02215 USA
来源：
EXPERIMENTAL HEMATOLOGY | 2004年 / 32卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
19
引用
收藏
页码：35 / 35
页数：1
相关论文
共 50 条
  • [31] Activated T cells from umbilical cord blood armed with anti-CD3 anti-CD20 bispecific antibody mediate specific cytotoxicity against CD20+targets with minimal allogeneic reactivity: a strategy for providing antitumor effects after cord blood transplants
    Thakur, Archana
    Sorenson, Carly
    Norkina, Oxana
    Schalk, Dana
    Ratanatharathorn, Voravit
    Lum, Lawrence G.
    TRANSFUSION, 2012, 52 (01) : 63 - 75
  • [32] The therapeutic potential of anti-CD20 - What do B-cells do?
    Eisenberg, R
    Looney, RJ
    CLINICAL IMMUNOLOGY, 2005, 117 (03) : 207 - 213
  • [33] Targeting Cytomegalovirus-Infected Cells Using T Cells Armed with Anti-CD3 x Anti-CMV Bispecific Antibody
    Lum, Lawrence G.
    Ramesh, Mayur
    Thakur, Archana
    Mitra, Subhashis
    Deol, Abhinav
    Uberti, Joseph P.
    Pellett, Philip E.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (07) : 1012 - 1022
  • [34] Anti-CD3ε induces splenic B220lo B-cell expansion following anti-CD20 treatment in a mouse model of allosensitization
    Todo, Tsuyoshi
    Wu, Gordon
    Chai, Ning-ning
    He, Yao
    Martins, Gislaine
    Gupta, Ankur
    Fair, Jeffrey
    Liu, Nai-you
    Jordan, Stanley
    Klein, Andrew
    INTERNATIONAL IMMUNOLOGY, 2012, 24 (08) : 529 - 538
  • [35] Immunotherapy of lymphomas with T cells modified by anti-CD20 scFv/CD28/CD3ζ recombinant gene
    Yu, Kang
    Hu, Yongxian
    Tan, Yinxia
    Shen, Zhijian
    Jiang, Songfu
    Qian, Honglan
    Liang, Bin
    Shan, Daming
    LEUKEMIA & LYMPHOMA, 2008, 49 (07) : 1368 - 1373
  • [36] TRANSLATIONAL FINDINGS FOR REGN1979, A HUMAN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY: FROM PRECLINICAL TO FIRST-IN-HUMAN STUDY IN PATIENTS WITH CD20+B-CELL MALIGNANCIES.
    Zhu, M.
    Smith, E.
    Kirshner, J.
    Toroghi, M.
    Davis, J.
    Di-Cioccio, A.
    Retter, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S103 - S103
  • [37] Adoptive immunotherapy of p53-mutated B-CLL with a trifunctional antibody (anti-CD3 x anti-CD20) and allogeneic donor lymphocyte transfusion
    Buhmann, R
    Stanglmaier, M
    Simoes, B
    Yang, T
    Ruf, P
    Lindhofer, H
    Kolb, HJ
    BLOOD, 2005, 106 (11) : 286B - 286B
  • [38] Adoptive immunotherapy of p53-mutated B-CLL with a trifunctional antibody (anti-CD3 x anti-CD20) and allogeneic donor lymphocyte transfusion
    Buhmann, R
    Stanglmaier, M
    Simoes, B
    Yang, T
    Ruf, P
    Lindhofer, H
    Kolb, HJ
    BONE MARROW TRANSPLANTATION, 2006, 37 : S226 - S227
  • [39] Transient chemokine production and antiviral effect in anti-CD3 and anti-CD28 activated monkey CD4+ T cells.
    Brice, GT
    Bostik, P
    Mayne, A
    Villinger, F
    Ansari, AA
    FASEB JOURNAL, 1998, 12 (04): : A295 - A295
  • [40] INVIVO ANTI-CD3 MAB ACTIVATES T-CELLS
    HIRSCH, R
    PLUZNIK, DH
    GRESS, R
    SACHS, DH
    BLUESTONE, JA
    FASEB JOURNAL, 1988, 2 (05): : A1243 - A1243
12345